Clinical Trials Directory

Trials / Unknown

UnknownNCT03136757

Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Centre Hospitalier Universitaire, Amiens · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Graft-versus-host disease (GVHD) is a frequent and severe complication of hematopoietic stem cell transplantation (HSC), and is responsible for significant early mortality despite prophylactic strategies developed in recent decades, Especially since it is resistant to first-line treatment. The present diagnosis is difficult, non-specific and is based on the combination of an evocative clinical context (CSH allograft, time to appearance before J100, characteristic clinical manifestations), suggestive anatomo-pathological analysis (predominantly inflammatory infiltrate Lymphocyte, mucosal edema and presence of apoptotic bodies), and the exclusion of any differential diagnosis (in particular serology / negative viral PCR). However, to date there is no molecular characterization of this manifestation, and therefore no specific treatment. The nCounter® nanostring technology allows the rapid and simple analysis of the simultaneous expression of a group of genes (up to 800 on the same sample), from a very small amount of RNA, and from samples with difficulty Such as fabrics already fixed to formaldehyde and included in paraffin. It allows the detection of a "molecular signature" of the tissue analyzed. No transcriptomic analysis has ever been performed on human tissues with GVHD.

Conditions

Interventions

TypeNameDescription
OTHERTranscriptomic analysis of GVHD biopsiesThe transcriptomic analysis of GVHD biopsies aims at: * to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier * to identify new intracellular signaling pathways that could lead to new therapeutic

Timeline

Start date
2017-08-20
Primary completion
2017-10-20
Completion
2017-10-20
First posted
2017-05-02
Last updated
2017-07-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03136757. Inclusion in this directory is not an endorsement.